Clinical Trials on Metastatic ER+ Breast Cancer in United Kingdom
Total 7863 results
-
Imperial College LondonMedical Research Council; ECMCRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerUnited Kingdom
-
Royal Marsden NHS Foundation TrustPfizer; Hoffmann-La RocheRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast CancerUnited Kingdom
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Royal Marsden NHS Foundation TrustPfizer; Breast Cancer NowRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Recurrent Breast Cancer | ER+ Breast CancerUnited Kingdom
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
-
TTC Oncology, LLCCompletedMetastatic ER+ Breast CancerUnited States
-
University of MiamiRecruitingBreast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
Janssen Research & Development, LLCCompletedPostmenopausal | Metastatic ER+ Her2- Breast CancerUnited States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsTerminatedAdvanced or Metastatic ER+ Breast CancerUnited States, France, Germany, Singapore, Italy, Japan, Belgium
-
Syndax PharmaceuticalsCompleted
-
AstraZenecaQuotient SciencesCompletedER-positive, HER2-negative Breast CancerUnited Kingdom
-
University of Wisconsin, MadisonContext Therapeutics Inc.TerminatedMetastatic Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
Hoffmann-La RocheRecruitingInoperable, Locally Advanced or Metastatic, ER-positive Breast CancerUnited States, Korea, Republic of, Spain, Australia, Israel
-
AstraZenecaCompletedER+ HER2- Advanced Breast CancerUnited States, United Kingdom, Korea, Republic of
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerUnited States, Korea, Republic of, Australia, Hong Kong, Taiwan, Malaysia, Thailand, Argentina, Belgium, Portugal
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer | Metastatic Breast Carcinoma | HER2+ Breast Cancer | Oligometastatic Breast CarcinomaUnited States
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerUnited States, Spain, United Kingdom
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
AstraZenecaCompletedPostmenopausal Women With ER+ HER2- Primary Breast CancerGermany, United Kingdom
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Royal Marsden NHS Foundation TrustPfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave... and other collaboratorsRecruitingHER2-negative Breast Cancer | ER+ Breast CancerUnited Kingdom, France
-
Sarah Sammons, MDDaiichi SankyoRecruitingBreast Cancer | Breast Cancer Female | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | ER-negative Breast Cancer | ER Positive Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Queen Mary University of LondonAstellas Pharma IncUnknownPrimary Breast Cancer ER+ve | Primary Breast Cancer AR+ve TNBNGermany, United Kingdom, Spain, United States, Ireland
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
AstraZenecaCompletedFGFR Inhibition, Pharmacokinetics, Biomarkers | ER+ Breast CancerCzech Republic, Italy, United Kingdom, Hungary, Germany, Romania, Belgium, France
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
The Methodist Hospital Research InstituteEli Lilly and CompanyRecruitingHER2-negative Breast Cancer | ER-Positive Breast CancerUnited States
-
Stanford UniversityUnited States Department of DefenseRecruitingBreast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerUnited States
-
Stemline Therapeutics, Inc.CompletedAdvanced ER+, HER2-Negative Breast CancerUnited States
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United Kingdom; Breakthrough Breast CancerUnknown
-
Cardiff UniversityWithdrawnMetastatic Breast CancerUnited Kingdom
-
Institute of Cancer Research, United KingdomTerminatedMetastatic Breast CancerUnited Kingdom
-
Dartmouth-Hitchcock Medical CenterRecruitingBreast Cancer | ER Positive Breast CancerUnited States
-
Western Regional Medical CenterTerminatedHER2-positive Breast Cancer | ER-positive Breast CancerUnited States
-
GTxWithdrawnER+ and AR+ Breast CancerUnited States
-
Ruth O'ReganUniversity of Rochester; Puma Biotechnology, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Royal Marsden NHS Foundation TrustCompletedMetastatic Breast CancerUnited Kingdom
-
Jennifer Lee Caswell-JinNational Cancer Institute (NCI); QED Therapeutics, Inc.TerminatedBreast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Eisai Inc.CompletedBreast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast CancerFrance, United Kingdom, United States
-
University of OxfordoxBRC; Vodafone UK Foundation; Centre for Statistics in Medicine; Oncology Clinical...CompletedMetastatic Colorectal Cancer | Metastatic Breast CancerUnited Kingdom
-
Abramson Cancer Center at Penn MedicineRecruitingBreast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | ER Positive Breast CancerUnited States
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
Synta Pharmaceuticals Corp.CompletedBreast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentSpain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer (MBC) | Locally Advance Breast Cancer (LABC)United Kingdom, Spain
-
Beth Israel Deaconess Medical CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Dana-Farber Cancer...CompletedBreast Cancer | Aromatase Inhibitors | ER+ Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
-
Imperial College LondonCancer Research UKCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerUnited Kingdom